All Phenotypes Tg(Mt1-Hgf)#Lmb MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Cdk4^tm1.1Bbd/Cdk4^tm1.1Bbd Krt14^tm1(cre)Wbm/Krt14⁺ Pard3^tm1Shoh/Pard3^tm1Shoh Tg(Mt1-Hgf)#Lmb/0	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J	MGI:6272611
cx2	Cdk4⁺/Cdk4⁺ Tg(Mt1-Hgf)#Lmb/0	B6.Cg-Cdk4^tm1.1Bbd Tg(Mt1-Hgf)#Lmb	MGI:6259550
cx3	Cdk4^tm1.1Bbd/Cdk4^tm1.1Bbd Tg(Mt1-Hgf)#Lmb/0	B6.Cg-Cdk4^tm1.1Bbd Tg(Mt1-Hgf)#Lmb	MGI:6259566
cx4	Cdk4^tm1.1Bbd/Cdk4⁺ Tg(Mt1-Hgf)#Lmb/0	B6.Cg-Cdk4^tm1.1Bbd Tg(Mt1-Hgf)#Lmb	MGI:6259577
tg5	Tg(Mt1-Hgf)#Lmb/0	B6.FVB-Tg(Mt1-Hgf)#Lmb	MGI:6259537

Allelic Composition	Cdk4^tm1.1Bbd/Cdk4^tm1.1Bbd Krt14^tm1(cre)Wbm/Krt14⁺ Pard3^tm1Shoh/Pard3^tm1Shoh Tg(Mt1-Hgf)#Lmb/0
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdk4^tm1.1Bbd mutation (0 available); any Cdk4 mutation (57 available)
Krt14^tm1(cre)Wbm mutation (0 available); any Krt14 mutation (36 available)
Pard3^tm1Shoh mutation (0 available); any Pard3 mutation (96 available)
Tg(Mt1-Hgf)#Lmb mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased incidence of tumors by chemical induction ( J:240961 )

• at 8-15 weeks after DMBA treatment, mice exhibit significantly increased melanoma multiplicity relative to control mice, with primary melanomas invading the dermis and showing tumor-associated angiogenesis

increased metastatic potential ( J:240961 )

• less than 15 weeks after DMBA treatment, mice show increased incidence of distal melanoma metastases in the lungs relative to control mice (57.1% versus 16.7%)

increased tumor growth/size ( J:240961 )

• in DMBA-treated mice, primary melanomas show an increased proliferative index, with a significantly higher number of PCNA^high melanoma cells relative to control mice, consistent with increased melanoma multiplicity

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:240961 )

Allelic Composition	Cdk4⁺/Cdk4⁺ Tg(Mt1-Hgf)#Lmb/0
Genetic Background	B6.Cg-Cdk4^tm1.1Bbd Tg(Mt1-Hgf)#Lmb

Find Mice

Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased incidence of tumors by chemical induction ( J:111992 )

• in a 2-step (DMBA/TPA) skin carcinogenesis protocol, all (18 of 18) mice develop slowly growing skin melanomas with an average of 12 cutaneous melanomas

• DMBA/TPA-induced melanomas involve the epidermo-dermal junction and show vertical invasive growth into the dermis; however, no proliferative activity of melanoma cells is detected by Ki67 staining

• 10 of 18 DMBA/TPA-treated mice also develop large subcutaneous cystic tumors filled with serous liquid and have to be sacrificed by 30 weeks of age

• all DMBA/TPA-treated mice develop on average 3 papillomas in the skin; these appear early after carcinogen treatment

increased skin tumor incidence ( J:111992 )

• at 30 weeks of age, untreated mice exhibit melanocytic nevi in skin

• however, untreated mice are all alive and healthy at 1 year of age

increased metastatic potential ( J:111992 )

• DMBA/TPA-treated mice show locoregional metastatic growth of melanoma cells in draining lymph nodes as well as numerous melanoma micrometastases in lung tissue

• in lymph nodes of DMBA/TPA-treated mice, melanoma cells are mainly spindle-shaped cells with little/no melanin that eventually disrupt lymph node architecture and displace lymphoid cells; however, heavily pigmented epitheloid melanoma cells are also observed

• in DMBA/TPA-treated mice, the average number of lung metastases is comparable to that in Cdk4^tm1.1Bbd/Cdk4⁺ Tg(Mt1-HGFSF)#Lmb/0 mice

integument

increased skin tumor incidence ( J:111992 )

• at 30 weeks of age, untreated mice exhibit melanocytic nevi in skin

• however, untreated mice are all alive and healthy at 1 year of age

immune system

abnormal axillary lymph node morphology ( J:111992 )

• at sacrifice, DMBA/TPA-treated mice show heavily pigmented axillar lymph nodes

abnormal inguinal lymph node morphology ( J:111992 )

• at sacrifice, DMBA/TPA-treated mice show heavily pigmented inguinal lymph nodes

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:111992 )

• in a 2-step (DMBA/TPA) skin carcinogenesis protocol, all (18 of 18) mice develop slowly growing skin melanomas with an average of 12 cutaneous melanomas

• 10 of 18 DMBA/TPA-treated mice also develop large subcutaneous cystic tumors filled with serous liquid and have to be sacrificed by 30 weeks of age

• all DMBA/TPA-treated mice develop on average 3 papillomas in the skin; these appear early after carcinogen treatment

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased incidence of tumors by chemical induction ( J:111992 )

• in a 2-step (DMBA/TPA) skin carcinogenesis protocol, all (16 of 16) mice show melanocytic nevi within the first weeks of life while still under TPA treatment

• all DMBA/TPA-treated mice develop widespread, rapidly growing skin melanomas and have to be sacrificed by 12 weeks of age due to melanomas >10 mm in diameter and systemic signs of illness; an average of ~48 cutaneous melanomas is observed

• DMBA/TPA-induced melanomas involve the epidermo-dermal junction and show vertical invasive growth into the dermis; at 12 weeks of age, vertical tumor thickness is larger than that in Cdk4^tm1.1Bbd/Cdk4⁺ Tg(Mt1-HGFSF)#Lmb/0 mice

• heavily pigmented epitheloid melanoma cells are arranged in bands and nests between lightly pigmented spindle-shaped melanoma cells

• only 3 of 16 DMBA/TPA-treated mice develop a single papilloma in skin

increased skin tumor incidence ( J:111992 )

• at 30 weeks of age, untreated mice exhibit a similar number of melanocytic nevi in skin as untreated Tg(Mt1-HGFSF)#Lmb/0 mice

increased cutaneous melanoma incidence ( J:111992 )

• untreated mice develop single, rapidly growing, spontaneous skin melanomas starting at ~30-40 weeks of age; ~20% of these mice have to be sacrificed by 1 year of age, with primary melanomas >10 mm in diameter

increased metastatic potential ( J:111992 )

• DMBA/TPA-treated mice show locoregional metastatic growth of melanoma cells in the draining lymph nodes as well as numerous melanoma micrometastases in lung tissue

• in lymph nodes of DMBA/TPA-treated mice, melanoma cells are mostly spindle-shaped cells with little/no melanin that eventually disrupt lymph node architecture and displace lymphoid cells; however, heavily pigmented epitheloid melanoma cells are also observed

• in DMBA/TPA-treated mice, the average number of lung metastases is significantly higher than that in DMBA/TPA-treated Cdk4^tm1.1Bbd/Cdk4⁺ Tg(Mt1-HGFSF)#Lmb/0 mice

• untreated mice with large spontaneous primary melanomas arising in skin also show locoregional metastases in adjacent draining lymph nodes as well as distal micrometastases in the lungs

increased tumor growth/size ( J:111992 )

• all DMBA/TPA-treated mice develop rapidly growing skin melanomas reaching >10 mm in diameter at 12 weeks of age

• few mitoses and a low % of Ki67 staining are noted in spindle-shaped melanoma cells near the invasion front, indicating proliferative activity of melanoma cells

integument

increased skin tumor incidence ( J:111992 )

• at 30 weeks of age, untreated mice exhibit a similar number of melanocytic nevi in skin as untreated Tg(Mt1-HGFSF)#Lmb/0 mice

increased cutaneous melanoma incidence ( J:111992 )

immune system

abnormal axillary lymph node morphology ( J:111992 )

• at sacrifice, DMBA/TPA-treated mice show heavily pigmented axillary lymph nodes

enlarged axillary lymph nodes ( J:111992 )

• at sacrifice, DMBA/TPA-treated mice show enlarged axillary lymph nodes due to growth of melanoma cells

abnormal inguinal lymph node morphology ( J:111992 )

• at sacrifice, DMBA/TPA-treated mice show heavily pigmented inguinal lymph nodes

enlarged inguinal lymph nodes ( J:111992 )

• at sacrifice, DMBA/TPA-treated mice show enlarged inguinal lymph nodes due to growth of melanoma cells

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:111992 )

• in a 2-step (DMBA/TPA) skin carcinogenesis protocol, all (16 of 16) mice show melanocytic nevi within the first weeks of life while still under TPA treatment

• heavily pigmented epitheloid melanoma cells are arranged in bands and nests between lightly pigmented spindle-shaped melanoma cells

• only 3 of 16 DMBA/TPA-treated mice develop a single papilloma in skin

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
skin melanoma		DOID:8923	OMIM:608035 OMIM:612263	J:111992

Allelic Composition	Cdk4^tm1.1Bbd/Cdk4⁺ Tg(Mt1-Hgf)#Lmb/0
Genetic Background	B6.Cg-Cdk4^tm1.1Bbd Tg(Mt1-Hgf)#Lmb

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cdk4^tm1.1Bbd mutation (0 available); any Cdk4 mutation (57 available)
Tg(Mt1-Hgf)#Lmb mutation (0 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased incidence of tumors by chemical induction ( J:111992 )

• in a 2-step (DMBA/TPA) skin carcinogenesis protocol, all (15 of 15) mice develop progressively growing melanomas and have to be sacrificed between 14 and 16 weeks of age with an average of 32 cutaneous melanomas

• DMBA/TPA-induced melanomas involve the epidermo-dermal junction and show vertical invasive growth in the underlying dermis

• only 3 of 15 DMBA/TPA-treated mice develop a single papilloma in skin

increased metastatic potential ( J:111992 )

• DMBA/TPA-treated mice show locoregional metastatic growth of melanoma cells in draining lymph nodes as well as numerous melanoma micrometastases in lung tissue

• in DMBA/TPA-treated mice, the average number of lung metastases is comparable to that in Tg(Mt1-HGFSF)#Lmb/0 mice

decreased tumor growth/size ( J:111992 )

• DMBA/TPA-induced melanomas grow with a slight delay relative to those in Cdk4^tm1.1Bbd/Cdk4^tm1.1Bbd Tg(Mt1-HGFSF)#Lmb/0 mice

immune system

abnormal axillary lymph node morphology ( J:111992 )

• at sacrifice, DMBA/TPA-treated mice show heavily pigmented axillary lymph nodes

enlarged axillary lymph nodes ( J:111992 )

• at sacrifice, DMBA/TPA-treated mice show enlarged axillary lymph nodes due to growth of melanoma cells

abnormal inguinal lymph node morphology ( J:111992 )

• at sacrifice, DMBA/TPA-treated mice show heavily pigmented inguinal lymph nodes

enlarged inguinal lymph nodes ( J:111992 )

• at sacrifice, DMBA/TPA-treated mice show enlarged inguinal lymph nodes due to growth of melanoma cells

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:111992 )

• DMBA/TPA-induced melanomas involve the epidermo-dermal junction and show vertical invasive growth in the underlying dermis

• only 3 of 15 DMBA/TPA-treated mice develop a single papilloma in skin

Allelic Composition	Tg(Mt1-Hgf)#Lmb/0
Genetic Background	B6.FVB-Tg(Mt1-Hgf)#Lmb

Find Mice

Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

reproductive system

reduced female fertility ( J:111992 )

• females are mostly not fertile

pigmentation

hyperpigmentation ( J:111992 )

• mice exhibit dark nose, ears, and paws

increased ear pigmentation ( J:111992 )

increased foot pigmentation ( J:111992 )

integument

increased ear pigmentation ( J:111992 )

increased foot pigmentation ( J:111992 )

growth/size/body

increased ear pigmentation ( J:111992 )

craniofacial

increased ear pigmentation ( J:111992 )

hearing/vestibular/ear

increased ear pigmentation ( J:111992 )

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 04/23/2024 MGI 6.23